InterPAD - DETAILS

Vorinostat, 149647-78-9, SAHA, suberoylanilide hydroxamic acid, Zolinza, N-hydroxy-N'-phenyloctanediamide, N1-hydroxy-N8-phenyloctanediamide, Suberanilohydroxamic acid, MK-0683, MK0683, Vorinostat (SAHA, MK0683), Octanediamide, N-hydroxy-N'-phenyl-, OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE, Vorinostat (SAHA), CCRIS 8456, N-Hyrdroxy-N'-phenyloctanediamide, NSC-701852, SHH, C14H20N2O3, CHEMBL98, MFCD00945317, NSC-748799, NSC-759852, 58IFB293JI, DTXSID6041133, CHEBI:45716, WIN64652, NSC701852, SAHA cpd, NCGC00168085-01, NCGC00168085-02, Vorinostat [USAN], Zolinza (TN) (Merck), N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide, DTXCID4021133, N'-hydroxy-N-phenyloctanediamide, Vorinostat MSD, SMR000486344, Zolinza (TN), CAS-149647-78-9, SR-05000000373, Vorinostat (JAN/USAN), Vorinostat [USAN:INN], MK 0683, vorinostatum, UNII-58IFB293JI, SKI390, HSDB 7930, 4lxz, Vorinostat(SAHA), Zolinza; SAHA, N1-hydroxy-N8-phenyl-octanediamide, SAHA, Suberoylanilide hydroxamic acid, 1zz1, VORINOSTAT [MI], SW-064652, VORINOSTAT [INN], VORINOSTAT [JAN], 8-(hydroxyamino)-8-oxo-N-phenyl-octanamide, VORINOSTAT [VANDF], cid_5311, SCHEMBL9018, VORINOSTAT [MART.], VORINOSTAT [WHO-DD], Suberoylanilidehydroxamic Acid, MLS001065855, MLS006011941, GTPL6852, VORINOSTAT [ORANGE BOOK], BDBM19149, Vorinostat (SAHA; MK0683), n-hydroxy-n'-phenyl-octanediamide, SUBERANILOHYDROXAMINIC ACID, 1t69, N-hydroxy-N''-phenyloctanediamide, BCPP000018, HMS2219L20, HMS3264D20, HMS3327C12, HMS3426G03, HMS3650D09, HMS3654G11, HMS3715E22, HMS3745M03, Pharmakon1600-01502267, BCP01858, EX-A2745, SAHA, >=98% (HPLC), Vorinostat,SAHA,Zolinza,MK-0683, Tox21_112605, Tox21_113623, Vorinostat,CAS:149647-78-9, HB1396, NSC748799, NSC759852, Octanediamide, N1-hydroxy-N8-phenyl, s1047, SK1390, AKOS015966648, Octanediamide, N1-hydroxy-N8-phenyl-, Tox21_112605_1, AC-1923, CCG-208659, CS-0589, DB02546, DG-0025, NSC 701852, NSC 748799, NSC 759852, SB17319, NCGC00168085-03, NCGC00168085-04, NCGC00168085-05, NCGC00168085-13, BP-25652, BP-30216, BV164560, HY-10221, SY009383, AM20030018, FT-0650593, H1388, NS00068618, SW199536-4, D06320, EN300-120641, AB00375377-07, AB00375377-08, AB00375377-09, AB01644613_25, A808935, Q905901, Vorinostat, SAHA, suberoylanilide hydroxamic acid, SR-05000000373-2, SR-05000000373-6, SR-05000000373-8, W-201327, BRD-K81418486-001-01-2, BRD-K81418486-001-10-3, BRD-K81418486-001-12-9, BRD-K81418486-001-13-7, BRD-K81418486-001-17-8, BRD-K81418486-001-18-6, Z1530532755, N-Hydroxy-N inverted exclamation mark -phenyloctanediamide, MK0683 , suberoylanilide hydroxamic acid , SAHA, 1227736-21-1

No.	Title	Href
1	Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors. Mol Med Rep. 2013 Jun;7(6):1838-44. doi: 10.3892/mmr.2013.1440.	`Click`

No.

Title

Href

Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors. Mol Med Rep. 2013 Jun;7(6):1838-44. doi: 10.3892/mmr.2013.1440.

Click

Name	Suberoylanilide hydroxamic acid (SAHA)
PubChem CID	5311
Molecular Weight	264.32g/mol
Synonyms	Vorinostat, 149647-78-9, SAHA, suberoylanilide hydroxamic acid, Zolinza, N-hydroxy-N'-phenyloctanediamide, N1-hydroxy-N8-phenyloctanediamide, Suberanilohydroxamic acid, MK-0683, MK0683, Vorinostat (SAHA, MK0683), Octanediamide, N-hydroxy-N'-phenyl-, OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE, Vorinostat (SAHA), CCRIS 8456, N-Hyrdroxy-N'-phenyloctanediamide, NSC-701852, SHH, C14H20N2O3, CHEMBL98, MFCD00945317, NSC-748799, NSC-759852, 58IFB293JI, DTXSID6041133, CHEBI:45716, WIN64652, NSC701852, SAHA cpd, NCGC00168085-01, NCGC00168085-02, Vorinostat [USAN], Zolinza (TN) (Merck), N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide, DTXCID4021133, N'-hydroxy-N-phenyloctanediamide, Vorinostat MSD, SMR000486344, Zolinza (TN), CAS-149647-78-9, SR-05000000373, Vorinostat (JAN/USAN), Vorinostat [USAN:INN], MK 0683, vorinostatum, UNII-58IFB293JI, SKI390, HSDB 7930, 4lxz, Vorinostat(SAHA), Zolinza; SAHA, N1-hydroxy-N8-phenyl-octanediamide, SAHA, Suberoylanilide hydroxamic acid, 1zz1, VORINOSTAT [MI], SW-064652, VORINOSTAT [INN], VORINOSTAT [JAN], 8-(hydroxyamino)-8-oxo-N-phenyl-octanamide, VORINOSTAT [VANDF], cid_5311, SCHEMBL9018, VORINOSTAT [MART.], VORINOSTAT [WHO-DD], Suberoylanilidehydroxamic Acid, MLS001065855, MLS006011941, GTPL6852, VORINOSTAT [ORANGE BOOK], BDBM19149, Vorinostat (SAHA; MK0683), n-hydroxy-n'-phenyl-octanediamide, SUBERANILOHYDROXAMINIC ACID, 1t69, N-hydroxy-N''-phenyloctanediamide, BCPP000018, HMS2219L20, HMS3264D20, HMS3327C12, HMS3426G03, HMS3650D09, HMS3654G11, HMS3715E22, HMS3745M03, Pharmakon1600-01502267, BCP01858, EX-A2745, SAHA, >=98% (HPLC), Vorinostat,SAHA,Zolinza,MK-0683, Tox21_112605, Tox21_113623, Vorinostat,CAS:149647-78-9, HB1396, NSC748799, NSC759852, Octanediamide, N1-hydroxy-N8-phenyl, s1047, SK1390, AKOS015966648, Octanediamide, N1-hydroxy-N8-phenyl-, Tox21_112605_1, AC-1923, CCG-208659, CS-0589, DB02546, DG-0025, NSC 701852, NSC 748799, NSC 759852, SB17319, NCGC00168085-03, NCGC00168085-04, NCGC00168085-05, NCGC00168085-13, BP-25652, BP-30216, BV164560, HY-10221, SY009383, AM20030018, FT-0650593, H1388, NS00068618, SW199536-4, D06320, EN300-120641, AB00375377-07, AB00375377-08, AB00375377-09, AB01644613_25, A808935, Q905901, Vorinostat, SAHA, suberoylanilide hydroxamic acid, SR-05000000373-2, SR-05000000373-6, SR-05000000373-8, W-201327, BRD-K81418486-001-01-2, BRD-K81418486-001-10-3, BRD-K81418486-001-12-9, BRD-K81418486-001-13-7, BRD-K81418486-001-17-8, BRD-K81418486-001-18-6, Z1530532755, N-Hydroxy-N inverted exclamation mark -phenyloctanediamide, MK0683 , suberoylanilide hydroxamic acid , SAHA, 1227736-21-1
Drug Type	Small molecule
Formula	C₁₄H₂₀N₂O₃
SMILES	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
InChI	1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
InChIKey	WAEXFXRVDQXREF-UHFFFAOYSA-N
CAS Number	149647-78-9
ChEMBL ID	CHEMBL98
ChEBI ID	CHEBI:45716
TTD ID	D0E7PQ
Drug Bank ID	DB02546
KEGG ID	D06320
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Homoharringtonine, Suberoylanilide hydroxamic acid (SAHA)
Partner Name	Homoharringtonine
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BID	hsa637
	Up-regulation	Activity	CASP3	hsa836
	Up-regulation	Activity	CASP8	hsa841
	Up-regulation	Activity	CASP9	hsa842
	Up-regulation	Expression	CYCS	hsa54205
	Up-regulation	Acetylation	H3C14	hsa126961
	Up-regulation	Acetylation	HRH4	hsa59340
	Up-regulation	Activity	PARP1	hsa142
	Up-regulation	Expression	TNFRSF10B	hsa8795
	Up-regulation	Expression	TNFSF10	hsa8743
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	Kasumi-1	Childhood acute myeloid leukemia with maturation	Homo sapiens (Human)	CVCL_0589
In Vitro Model	THP-1	Childhood acute monocytic leukemia	Homo sapiens (Human)	CVCL_0006
In Vivo Model	3 to 4-week-old female mice were inoculated subcutaneously with 1×10⁷ THP-1 cells (in 0.1 ml volume) into the hind flanks.
Result	The synergistic effect between HHT and SAHA was blocked partially using a specific anti‑TRAIL antibody. The combination therapy was also found to significantly inhibit the growth of leukemia xenografts in vivo with enhanced apoptosis. These results indicate that, by regulating the induction of TRAIL and activation of the TRAIL apoptotic pathway, it is possible to administer HHT at low concentrations in combination with SAHA as an effective therapeutic approach for the treatment of AML.